Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease.

• Given the slow and variable clinical course of Alzheimer disease, very large and extended clinical trials are needed to identify a beneficial clinical effect of disease-modifying treatments. Therefore, biomarkers are essential to prove that an anti-β-amyloid (Aβ) drug candidate affects both Aβ metabolism and plaque load as well as downstream pathogenic mechanisms.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Neurosciences (hsv//eng)

Nyckelord

Aged

Alzheimer Disease

cerebrospinal fluid

drug therapy

epidemiology

Amyloid beta-Peptides

cerebrospinal fluid

Antibodies

Monoclonal

Humanized

therapeutic use

Biological Markers

cerebrospinal fluid

Cohort Studies

Double-Blind Method

England

epidemiology

Female

Finland

epidemiology

Humans

Immunotherapy

methods

Male

Middle Aged

Peptide Fragments

cerebrospinal fluid

Treatment Outcome

United States

epidemiology

tau Proteins

cerebrospinal fluid

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)